Digital Sponsored Antiviral development in the age of AI: From pre-IND to earl... hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.
R&D Sponsored The future of cardiometabolic trials: From obesity to outcom... Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO
R&D Sponsored Best practices in cardiometabolic trial design: Planning and... Cardiometabolic disease is not a single entity. It is a broad spectrum of disorders that share common drivers.
R&D Sponsored Obesity, complexity, and the lab: What 2025 taught us, and w... The complexity of working with the patient population in obesity continues to challenge traditional trial design. hVIVO looks to the year ahead.
R&D Sponsored Unlocking the future of obesity treatment Obesity is more than a number on the scale, it’s a complex, malignant disease linked to diabetes, cardiovascular conditions, and even certain cancers.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.